Biotech Values

[DewDiligence]

IFRX IPOs 7.7M* shares @$15—insiders buy 40% of IPO shares:

https://www.renaissancecapital.com/IPO-Center/News/52353/Rare-disease-biotech-InflaRx-prices-IPO-at-$15-midpoint
https://www.renaissancecapital.com/Profile/IFRX/InflaRx/IPO

We are a clinical-stage biopharmaceutical company focused on applying our proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Our lead product candidate, IFX-1, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

We are developing IFX-1 for the treatment of HS, a chronic debilitating systemic inflammatory skin disease, for which we plan to initiate a Phase IIb clinical trial in the 1Q18. Beyond HS, we intend to develop IFX-1 and other proprietary antibodies to address a wide array of complement-mediated diseases with significant unmet needs, including AAV, a rare, life-threatening autoimmune disease.

*Assuming exercise of underwriter’s option.